Monday, April 5, 1993
Individual and collective
Sorting through the wreckage of the biotech financial markets is a useful exercise because it provides some insights into the nature of the industry and the kinds of attitudes that may be useful going forward.
First of all, it's about time that equity prices reflect the individual behavior of bioscience companies, including the meeting of clear product development milestones, the shrewdness of clinical trial design, the robustness of product portfolios (especially by companies already in the market), and the quality of the scientific and management underpinnings. As